AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06741566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal dexmedetomidine
Description: 1.5 mic/kg on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
Study NCT06751459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEMO Patch 2 - 14-day Monitoring
Description: A wearable ECG monitoring device used for continuous 14-day monitoring to detect atrial arrhythmias during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to assess early recurrence of atrial arrhythmias.
Study NCT06751459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEMO Patch 2 - 1-day Monitoring
Description: A wearable ECG monitoring device used for 1-day monitoring during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to detect early recurrence of atrial arrhythmias.
Study NCT06751459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEMO Link
Description: A supplementary ECG monitoring device used alongside MEMO Patch 2 during the 1st monitoring session.
Study NCT06751459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEMO Link
Description: A supplementary ECG monitoring device used alongside MEMO Patch 2 during the 1st monitoring session.
Study NCT05453188 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental
Description: Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.
Study NCT05453188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.
Study NCT06755463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure education
Description: Participants will undergo acupressure therapy for 8 weeks, with twice-weekly sessions between 8:00 AM and 10:00 AM. A certified practitioner will train participants on target points, pressure techniques, frequency, and duration. Practical demonstrations will ensure correct application. Groups of up to 10 participants will be trained in a comfortable setting and practice techniques under supervision until proficient. The treatment protocol, based on literature, focuses on beta-endorphin and hypocretin levels, cognition, and patient-reported outcomes (pain, fatigue, depression, and quality of life). Participants will apply 3-5 kg pressure for 2 minutes per point at 12 symmetrical points (LI4, SP6, GV20, HT7, EX-HN3, LV3) using rhythmic movements, totaling 24 minutes. They will receive a diary to track home practices and a visual guide explaining each point's location and steps for application.
Study NCT05453188 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.
Study NCT05453188 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Control
Description: Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.
Study NCT04851990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To Better Days Large Patch
Description: Large patch containing vitamin D \& Dextrose for transdermal absorption
Study NCT04851990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To Better Days Small Patch
Description: Small patch containing vitamin D \& Dextrose for transdermal absorption
Study NCT06339385 — intervention group
Intervention type: BEHAVIORAL
Intervention: PADIS assessment
Description: Hospital and nursing records from the 24 hours preceding enrollment were examined to document the assessment rate of pain, agitation-sedation, and delirium.
Study NCT05051696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H101
Description: Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
Study NCT05202327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
Study NCT05202327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo contained corn starch.
Study NCT05202327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contained corn starch.
Study NCT05268185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderna Booster Vaccine
Description: Participants assigned to this intervention will be given the recommendation to receive the Moderna vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, Moderna booster (0.25 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
Study NCT05268185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer Booster Vaccine
Description: Participants assigned to this intervention will be given the recommendation to receive the Pfizer vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, the Pfizer booster (0.30 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
Study NCT06754332 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: human chorionic gonadotropin
Description: The POI patients receive a single intramuscular injection of 10,000 units of human chorionic gonadotropin.
Study NCT06755697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular US-guided hypertonic dextrose injection, IA group
Description: IA injection: 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected. The ultrasound transducer (L18-4, Philips EPI Q5) is placed transversely over the patient's suprapatellar pouch while the patient lies supine with the knee actively extended and ankle dorsiflexed. The injectate will be injected into the suprapatellar pouch via transverse view, in-plane, lateral-to-medial approach with a 3.8 cm 22-gauge needle under US guidance.~Physical therapy: The physical therapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 4 weeks.
Study NCT06755697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extra-articular US-guided injection targeting MRI-positive lesion sites, EA group.
Description: Patients in the EA group will receive MRI examination of the knee without contrast. Detailed physical examinations (PE) will also be done for each subject. The PEs include inspection, palpation for local tenderness and crepitus, signs of effusion, assessment of range of motion, provocative meniscal testing, and ligamentous tests for laxity. A total of 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected to the target areas which has been shown abnormal on MRI images with a 3.8 cm 22-gauge needle under US guidance. For lesions of the deep structures or bone marrow lesion, a 7-cm 23 or 21 gauge needles may be used. Same as the IA group, EA hypertonic dextrose injection will be done at the 0, 2nd, and 4th weeks, as well as physical therapy during the first 4 weeks.
Study NCT06751745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Emotional Intelligence Training
Description: The intervention is a 4-week online Emotional Intelligence (EI) training program for Bangladeshi youth. It includes weekly one-hour sessions focusing on self-awareness, self-regulation, social awareness, and relationship management. Led by experts, the program uses interactive activities and practical exercises to enhance emotional skills. Pre- and post-training assessments with the Bengali Emotional Intelligence Scale measure outcomes.
Study NCT06751680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal and Subserratus Plane Block
Description: Upon entry, electrocardiogram (ECG), blood pressure, and oxygen saturation were monitored. The patient is placed in the prone position with their arms abducted and internally rotated. Ultrasound equipment (SonoSite Edge II; Fujifilm SonoSite, Bothell, WA, USA) with a linear 13-6 MHz transducer (HFL50x; Fujifilm SonoSite, Bothell, WA, USA) was used. Each nerve block was performed by initially injecting a 5 mL test dose, observing for clinical signs of pain relief in the affected thoracic dermatome, and then injecting the remaining volume of medication after confirmation of the injection site. Patients received ultrasound-guided nerve blocks every 48 hours, for a total of three treatments.The RISS block is a composite nerve block technique that involves two injection sites, located in the inter-rhomboid plane and the sub-serratus plane, respectively. The choice of block plane depended on the patient's site of pain.
Study NCT06751680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVB block
Description: The patient is placed in the prone position with their arms abducted and internally rotated. Ultrasound equipment (SonoSite Edge II; Fujifilm SonoSite, Bothell, WA, USA) with a linear 13-6 MHz transducer (HFL50x; Fujifilm SonoSite, Bothell, WA, USA) was used. Each nerve block was performed by initially injecting a 5 mL test dose, observing for clinical signs of pain relief in the affected thoracic dermatome, and then injecting the remaining volume of medication after confirmation of the injection site. Patients received ultrasound-guided nerve blocks every 48 hours, for a total of three treatments.After confirming needle tip placement, 10 mL of 0.5% ropivacaine with 10 mg of triamcinolone acetonide was slowly injected in divided doses, observing for the spread of the local anesthetic to ensure adequate distribution within the PVS for effective block. If multiple nerves were involved, the injection sites were spaced one thoracic vertebral segment apart.
Study NCT06752603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1110
Description: ONO-1110 tablets once a day
Study NCT06752603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study NCT04604951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation
Description: This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.
Study NCT04175639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Pain Coping Skills Training (mPCST)
Description: Participating in Mobile Health Pain Coping Skills Training will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic. The therapist delivering the intervention will be at Duke University Medical Center, and patients will be at their community clinic.
Study NCT05028218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3824 tablets
Description: TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways.
Study NCT05415813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Compression
Description: It includes conventional Physical therapy, hot packs (75°C) for 20 minutes, and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold, and 10-second relaxation between two repetitions) as a baseline treatment. For the Ischemic compression, the patient will be in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position physiotherapist will apply gradually increasing pressure to the Trigger points until the subject perceived the first noticeable pain. At that moment, the pressure will be maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure will be increased until the discomfort appears again. This process will be maintained for 90 seconds.
Study NCT05415813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression with Muscle Energy Technique
Description: The Participants will receive all the treatments given to the active comparator group and they will also receive the Muscle Energy Technique treatment in supine position and the practitioner will stabilize the shoulder of the affected side with one hand, while the ear/mastoid area of the affected side will be held by the opposite hand. The head and neck were then bent towards the contralateral side, flexed, and ipsilaterally rotated. The subjects will then shrug the stabilized shoulder towards the ear at a sub-maximal pain-free effort (20% of the available strength). The isometric contraction will be held for 7-10s. This position will be maintained for 30 seconds and repeated three to five times per treatment session. Treatment sessions will be given on alternate days.
Study NCT04118153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL) per dose.
Study NCT05938647 — intervention group
Intervention type: OTHER
Intervention: Risk factor: group 3
Description: Severe dengue, no shock. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.
Study NCT05938647 — intervention group
Intervention type: OTHER
Intervention: Risk factor: group 4
Description: Dengue shock syndrome. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes
Study NCT05910528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7790121
Description: RO7790121 will be administered during the Induction, Maintenance and OLE period.
Study NCT06755489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 530 mg tablets containing microcrystalline cellulose, rice bran, bitter cocoa powder table 530 mg. 1 tablet three times a day
Study NCT06755489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GABA
Description: 530 mg tablets containing Gamma-aminobutyric acid (GABA) and different bulking agent as microcrystalline cellulose, calcium carbonate, lemon balm d.e. Leaves (melissa officinalis l. - maltodextrin) tit. 2% in rosmarinic acid, anti-caking agents: silicon dioxide, vegetable magnesium stearate. 1 tablet three times a day
Study NCT05461872 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06477575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurocognitive therapy based on new technologies
Description: The cognitive neurorehabilitation program is based on gaming through the use of the Nintendo Switch device. The following games have been chosen: Pufferfish, Hex Egg, Mystic Totem, Thor's Thunder, since they are games that work on selective attention, concentration and processing speed, which are the variables to be studied in this project.~Hardware: Nintendo Switch Software: 60 in 1 game Games: Pufferfish, Hex Egg, Mystic Totem, Thor's Thunder. Therapy time: 30 minutes effective. Number of Sessions: 2 per week / Number of weeks: 8 Total number of intervention sessions: 16 sessions Place: Thercli Center (Don Benito).
Study NCT06477575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional neurocognitive therapy
Description: The cognitive neurorehabilitation program for group active comparator is based on playing more conventional board games that work on selective attention, concentration and processing speed, which are the variables to be studied in this project.~Traditional games and token book. Games: Dobble, Lynx, Crazy cups, Jungle speed, animalea, ghost. Card: Stimulate and learn level 3 and 4. Therapy time: 30 minutes effective. No. of sessions: 2 per week / No. of weeks: 8 Total number of intervention sessions: 16 sessions Place: Thercli Center (Don Benito).
Study NCT04134455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh reinforcement
Description: Once the surgery is over. The closure is made with the 4: 1 rule, then an onlay mesh is placed that exceeds 3 cm on each side the wound is fixed with suture.
Study NCT06143826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercises
Description: Progressive muscle relaxation exercises involve contracting and relaxing 16 muscle groups in the body (hand, upper arm, forearm, forehead, nose, cheek, chin, neck, shoulder, chest, abdomen, waist, stomach, calf, hip, foot). During the exercise, the individual perceives the changes in the muscles during the contraction and relaxation of the muscles. Relaxation exercise is applied along with correct and deep breathing.
Study NCT04134455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RTL reinforcement
Description: Once the surgery is finished, the ared is reinforced by placing a longitudinal suture parallel to the edge of the wound 0.5 cm, then the wound is closed with a 4: 1 rule but the suture enters lateral to the reinforcement suture
Study NCT06505707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Seeking Behavior Training Based on Motivational Interviewing Techniques
Description: The Effect of Health Seeking Behavior Training Based on Motivational Interviewing Techniques on Health Seeking Behavior, Illness Self-Management and Anxiety in Migrant Elderly Women with Chronic Diseases.
Study NCT06418724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR). EGFR is over-expressed in many human cancers, including colorectal cancers.
Study NCT06418724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with its ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). Engagement of PD-1 with its ligands PD-L1 and PD-L2, which are expressed by antigen presenting cells and may be expressed by tumour cells and/or other cells in the tumour microenvironment, results in inhibition of T cell function such as proliferation, cytokine secretion, and cytotoxic activity. Cemiplimab potentiates T cell responses, including antitumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.
Study NCT05276375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchipret
Description: Bronchipret syrup (3x 5,4 ml daily) until day 14
Study NCT05720338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19 French Blake Drain
Description: 19 French Blake Intraperitoneal Drain will be placed near the pancreatic resection margin
Study NCT06095297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing Speed Training
Description: Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to rapidly distinguish targets from decoys, which trains how rapidly the player processes information received through their senses.
Study NCT06095297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-lab Instrumental Activities of Daily Living Training
Description: Participant will receive shaping on IADLS. Participants will receive training on everyday tasks with important cognitive components, in which the difficulty is increased in small steps over the course of treatment.
Study NCT06095297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-lab Brain Health Training
Description: Participants will receive training on healthy eating, sleeping, and relaxation techniques that have been shown to improve brain health.
Study NCT06115642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study NCT05028153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Oral Liquid Product
Description: 10 mg/kg for 3 consecutive days
Study NCT05028153 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mixture
Description: Placebo mixture containing no active substance